Education
About Us
Working with TipRanks
Follow Us
AlzChem Group AG (GB:0ACT)
LSE:0ACT
Earnings Data
Report Date
Apr 30, 2026TBA (Not Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
―Last Year’s EPS
1.44Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveys a positive operational and financial story: the company delivered a record year with strong margin expansion, robust specialty segment performance, improved net profit and a healthy cash position while advancing major growth projects (creatine, nitroguanidine, U.S. site). Near‑term challenges include a weak Basics & Intermediates segment, a planned six‑month furnace shutdown (≈EUR 15m headwind in 2026), FX and energy cost pressure, and sizeable ongoing CapEx that raises timing and funding risks. On balance, the achievements and growth investments materially outweigh the near‑term negatives, positioning the company for meaningful medium‑term upside if projects execute as planned.Company Guidance
Record Annual Results and Sales
Consolidated sales of EUR 562 million (≈ +EUR 8 million YoY). Company states 2025 was the most successful financial year and largely achieved the guidance corridor (~EUR 580m midpoint).
Strong EBITDA Growth and Margin Expansion
Group EBITDA ~EUR 116.5 million, up ≈11% YoY (≈ +EUR 11m). EBITDA margin improved to 20.7% (exceeding the >20% long-term target and prior year ~19%).
Higher Net Profit and Increased Dividend
Group net result after tax of EUR 64 million, up ≈18% YoY. Earnings per share rose similarly and management proposed a dividend increase of +17% to EUR 2.10.
Specialty Chemicals Outperformance
Specialty Chemicals sales ≈ EUR 380 million, up 8.8% YoY (Q4 +9.2%). Segment EBITDA rose to ~EUR 107 million (+13.6% YoY from ≈EUR 94m). Growth driven by Human Nutrition (creatine), Custom Manufacturing and Defense.
Healthy Cash Position and Positive Free Cash Flow
Positive net cash position of EUR 31 million at year-end. Despite elevated CapEx, free cash flow remained positive; operating cash flow benefited from ~EUR 60 million customer grants and other timing effects.
Major Growth Investments on Track
Approved creatine expansion program (≈EUR 120 million) with phased commissioning from H2 2027 and expected additional annual sales potential in the initial 3‑digit million range. Nitroguanidine expansion progressing (installation ongoing; target commissioning mid‑2026). U.S. site selection nearly complete and initial cost submissions to DoD accepted.
Market Momentum & Strategic Positioning
Creapure/Creavitalis brand awareness rising; incremental capacity put on line in Q3/Q4 2025 provides ~20–25% more creatine quantities for 2026. Free float increased to ~74%, supporting market profile (toward MDAX range).
GB:0ACT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GB:0ACT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 27, 2026 | €157.50 | €149.79 | -4.90% |
Oct 30, 2025 | €147.00 | €160.77 | +9.37% |
Jul 30, 2025 | €144.00 | €133.67 | -7.18% |
Apr 30, 2025 | €103.25 | €107.53 | +4.15% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does AlzChem Group AG (GB:0ACT) report earnings?
AlzChem Group AG (GB:0ACT) is schdueled to report earning on Apr 30, 2026, TBA (Not Confirmed).
What is AlzChem Group AG (GB:0ACT) earnings time?
AlzChem Group AG (GB:0ACT) earnings time is at Apr 30, 2026, TBA (Not Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of AlzChem Group AG stock?
The P/E ratio of AlzChem Group AG is N/A.
What is GB:0ACT EPS forecast?
Currently, no data Available